Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Penny Moore

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Nursing Management|May 24, 2013
Regional fellowship bridges gap between practice and academiaSusan Mace Weeks, Kathy Baker, Deborah Behan, et al.
Mbio|March 30, 2022
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 VaccinesGary McLean, Jeremy Kamil, Benhur Lee, et al.
Vaccines|February 5, 2020
Immunogenicity of HIV-1 Vaccines Expressing Chimeric Envelope Glycoproteins on the Surface of Pr55 Gag Virus-Like ParticlesRosamund Chapman, Michiel van Diepen, Shireen Galant, et al.
Retrovirology|July 5, 2006
Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120James M Binley, Stacie Ngo-Abdalla, Penny Moore, et al.
Msphere|December 28, 2020
Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV InfectionM Muenchhoff, A W Chung, J Roider, et al.
BMJ Open|July 6, 2019
Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trialSharana Mahomed, Nigel Garrett, Edmund Capparelli, et al.
Iscience|December 17, 2025
Safety and immunogenicity of DNA omicron booster Alveavax-v1.2 in Ad26.COV2.S-vaccinated adultsMaximilian Schons, Tobias Odendahl, James A Smith, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2025
Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV VaccineRaquel Matavele Chissumba, Gaurav Kwatra, Patrícia Ramgi, et al.
Iscience|June 22, 2026
Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activitySven Kratochvil, Maximilian Kullmann, Henning Gruell, et al.
BMJ Open|November 27, 2020
Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trialSharana Mahomed, Nigel Garrett, Quarraisha A Karim, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Nursing Management|May 24, 2013
Regional fellowship bridges gap between practice and academiaSusan Mace Weeks, Kathy Baker, Deborah Behan, et al.
Mbio|March 30, 2022
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 VaccinesGary McLean, Jeremy Kamil, Benhur Lee, et al.
Vaccines|February 5, 2020
Immunogenicity of HIV-1 Vaccines Expressing Chimeric Envelope Glycoproteins on the Surface of Pr55 Gag Virus-Like ParticlesRosamund Chapman, Michiel van Diepen, Shireen Galant, et al.
Retrovirology|July 5, 2006
Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120James M Binley, Stacie Ngo-Abdalla, Penny Moore, et al.
Msphere|December 28, 2020
Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV InfectionM Muenchhoff, A W Chung, J Roider, et al.
BMJ Open|July 6, 2019
Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trialSharana Mahomed, Nigel Garrett, Edmund Capparelli, et al.
Iscience|December 17, 2025
Safety and immunogenicity of DNA omicron booster Alveavax-v1.2 in Ad26.COV2.S-vaccinated adultsMaximilian Schons, Tobias Odendahl, James A Smith, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2025
Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV VaccineRaquel Matavele Chissumba, Gaurav Kwatra, Patrícia Ramgi, et al.
Iscience|June 22, 2026
Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activitySven Kratochvil, Maximilian Kullmann, Henning Gruell, et al.
BMJ Open|November 27, 2020
Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trialSharana Mahomed, Nigel Garrett, Quarraisha A Karim, et al.
Pageof 3